SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001213900-24-054352
Filing Date
2024-06-20
Accepted
2024-06-20 17:16:23
Documents
14
Period of Report
2024-06-19
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0208210-8k_elevai.htm   iXBRL 8-K 27266
2 FORM OF UNSECURED REVOLVING LINE OF CREDIT PROMISSORY NOTE ea020821001ex10-1_elevai.htm EX-10.1 15927
  Complete submission text file 0001213900-24-054352.txt   224774

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE elab-20240619.xsd EX-101.SCH 3033
4 XBRL LABEL FILE elab-20240619_lab.xml EX-101.LAB 34240
5 XBRL PRESENTATION FILE elab-20240619_pre.xml EX-101.PRE 22371
17 EXTRACTED XBRL INSTANCE DOCUMENT ea0208210-8k_elevai_htm.xml XML 3795
Mailing Address 120 NEWPORT CENTER DRIVE STE 250 NEWPORT BEACH CA 92660
Business Address 120 NEWPORT CENTER DRIVE STE 250 NEWPORT BEACH CA 92660 18667944940
Elevai Labs Inc. (Filer) CIK: 0001840563 (see all company filings)

IRS No.: 851399981 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41875 | Film No.: 241057466
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)